Nivalis Therapeutics, Inc. (NASDAQ:ALPN) has been assigned a consensus recommendation of “Hold” from the nine research firms that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $6.35.

Several research firms have recently weighed in on ALPN. ValuEngine cut shares of Nivalis Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 11th. Zacks Investment Research lowered shares of Nivalis Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 10th. Finally, Ladenburg Thalmann Financial Services began coverage on shares of Nivalis Therapeutics in a research report on Thursday, July 27th. They issued a “buy” rating and a $17.00 price target for the company.

Nivalis Therapeutics (NASDAQ:ALPN) traded down 6.92% during trading on Friday, reaching $11.03. The company’s stock had a trading volume of 22,693 shares. The stock’s market cap is $43.17 million. The firm’s 50-day moving average is $10.84 and its 200-day moving average is $9.71. Nivalis Therapeutics has a 52-week low of $7.20 and a 52-week high of $30.40.

TRADEMARK VIOLATION NOTICE: “Nivalis Therapeutics, Inc. (ALPN) Given Consensus Recommendation of “Hold” by Analysts” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at

Nivalis Therapeutics Company Profile

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

Analyst Recommendations for Nivalis Therapeutics (NASDAQ:ALPN)

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with's FREE daily email newsletter.